MNLO Menlo Therapeutics Announces Late-Breaking Oral Presentation at the American Academy of Dermatology Annual Meeting for Serlopitant,
Pruritus associated with psoriasis.
Phase 2 data released December 10, 2018 – primary endpoint met. $MNLO Presentation of data March 2, 2019 1pm at American Academy of Dermatology Annual Meeting. Phase 3 planned for 2019.
$MNLO has approximately 77.80% Institutional Ownership and 19.12% Insider Ownership, with a rather low float of about 18M outstanding shares.